Purpose of review SGLT2 inhibitors (SGLT2i) are new drugs for patients with heart failure
(HF) irrespective of diabetes. However, the mechanisms of SGLT2i in HF remain elusive …

Sodium-glucose cotransporter 2 (SGLT2) inhibitors exert hypoglycemic and diuretic effects
by inhibiting the absorption of sodium and glucose from the proximal tubule. Currently …

In recent years, GLP-1 receptor agonists (GLP-1RA), and SGLT-2 inhibitors (SGLT-2i) have
become available, which have become valuable additions to therapy for type 2 diabetes as …

Objectives The use of sodium-glucose cotransporter-2 inhibitors (SGLT2-Is) has resulted in
significant benefits in patients with heart failure irrespective of left ventricular ejection fraction …

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are emerging as a new treatment
strategy for heart failure with reduced ejection fraction (HFrEF) and—depending on the …

The impressive results of recent clinical trials with glucagon-like peptide-1 receptor agonists
(GLP-1Ra) and sodium glucose transporter 2 inhibitors (SGLT-2i) in terms of cardiovascular …

Drug therapies for people with heart failure and preserved ejection fraction (HFpEF) are
often limited to diuretics to improve symptoms as no therapies demonstrate a mortality …

Background Although the benefits of sodium–glucose cotransporter 2 inhibitors (SGLT2i) on
cardiovascular events have been reported in patients with type 2 diabetes mellitus (T2DM) …

Background Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous
syndrome, with several underlying etiologic and pathophysiologic factors. The presence of …

Background Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the urinary albumin-
to-creatinine ratio (UACR) in patients with elevated levels of albuminuria in the presence or …